Last 47 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -7.84 | — | — | — | — | — | — | 6.84 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 22.56 | 56.94 | 40.97 | 9.84 | 17.00 | 8.14 | 3.43 | 1.70 | 2.82 | 2.76 | 2.10 | 1.13 | 1.17 | 1.34 | 1.53 | 4.83 | 6.35 | 8.22 | 10.09 | 24.98 | 33.17 |
| — | +599.2% | +1095.1% | +478.0% | +502.9% | +195.5% | +63.1% | +50.6% | +140.2% | +105.4% | +37.3% | -76.6% | -81.5% | -83.7% | -84.8% | -80.7% | -80.8% | -70.3% | -73.7% | -23.3% | +34.1% | |
| P/B Ratio | 7.00 | 2.56 | 3.09 | 9.55 | 9.42 | — | 10.44 | 3.27 | 5.56 | 3.25 | 1.44 | 0.82 | 0.71 | 0.56 | 0.55 | 1.16 | 1.46 | 1.55 | 1.65 | 3.68 | 4.13 |
| — | — | -70.4% | +192.1% | +69.3% | — | +627.3% | +296.7% | +682.3% | +481.8% | +161.5% | -28.9% | -51.2% | -63.9% | -66.7% | -68.4% | -64.7% | -55.3% | -54.8% | +29.7% | +62.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | 4.38 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | 3.74 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 98.6% | 100.0% | 98.3% | 100.0% | 100.0% | 72.7% | 81.6% | 58.5% | 60.6% | 69.5% | 48.5% | 65.9% | 67.3% | 71.7% | 79.0% | 76.3% | 78.6% | 75.4% | 78.7% |
| — | 0.0% | -1.4% | +37.6% | +20.5% | +70.8% | +65.1% | +4.5% | +68.2% | -11.2% | -10.0% | -3.1% | -38.6% | -13.7% | -14.4% | -4.9% | +0.3% | +4.6% | +3.9% | -7.6% | -3.4% | |
| Operating Margin | -236.8% | -417.9% | -352.3% | -87.5% | -267.4% | -324.2% | -425.8% | 49.2% | -142.4% | -211.9% | -163.7% | -140.3% | -185.8% | -246.8% | -623.8% | -185.7% | -158.6% | -216.8% | -463.6% | -451.5% | -455.8% |
| — | -28.9% | +17.3% | -278.0% | -87.9% | -53.0% | -160.1% | +135.1% | +23.4% | +14.2% | +73.8% | +24.4% | -17.2% | -13.9% | -34.6% | +58.9% | +65.2% | +44.3% | -0.2% | +4.3% | -32.8% | |
| Net Margin | -297.1% | -401.0% | -413.4% | -165.4% | -301.3% | -372.2% | -486.4% | 24.9% | -153.6% | -222.9% | -170.1% | -176.2% | -189.8% | -249.4% | -634.5% | -271.0% | -249.9% | -736.9% | -364.2% | -582.4% | -520.5% |
| — | -7.7% | +15.0% | -764.8% | -96.1% | -67.0% | -186.0% | +114.1% | +19.1% | +10.6% | +73.2% | +35.0% | +24.0% | +66.2% | -74.2% | +53.5% | +52.0% | -66.3% | +30.0% | -16.6% | -44.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -217.9% | -5.5% | -13.5% | -41.3% | -116.7% | — | -136.6% | 13.2% | -57.6% | -50.7% | -28.6% | -29.0% | -25.7% | -23.4% | -45.1% | -15.3% | -13.6% | -29.8% | -14.0% | -19.7% | -15.2% |
| — | — | +90.1% | -411.4% | -102.5% | — | -378.4% | +145.7% | -124.1% | -117.3% | +36.7% | -89.1% | -89.7% | +21.7% | -221.2% | +22.1% | +10.8% | -125.7% | -18.3% | -88.6% | -69.9% | |
| ROA | -56.2% | -4.4% | -8.6% | -12.4% | -14.0% | -17.9% | -18.2% | 2.4% | -11.4% | -14.2% | -9.3% | -10.0% | -9.8% | -9.7% | -21.5% | -8.0% | -7.2% | -16.9% | -8.4% | -12.2% | -9.8% |
| — | +75.6% | +52.6% | -622.6% | -22.7% | -26.6% | -96.0% | +123.7% | -16.2% | -46.3% | +57.0% | -25.1% | -36.2% | +42.6% | -155.1% | +34.2% | +26.6% | -90.0% | -2.8% | -58.2% | -40.0% | |
| ROIC | -57.2% | -4.0% | -7.1% | -8.0% | -28.7% | -52.2% | -34.4% | 8.7% | -12.5% | -15.6% | -13.1% | -11.7% | -13.8% | -13.5% | -28.8% | -7.2% | -5.8% | -5.8% | -11.7% | -10.0% | -9.5% |
| — | +92.3% | +79.4% | -191.1% | -129.6% | -233.8% | -162.5% | +174.7% | +9.7% | -16.0% | +54.5% | -62.5% | -136.6% | -131.0% | -146.7% | +28.0% | +38.4% | +33.1% | -43.9% | -38.6% | -61.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.66 | 0.15 | 0.25 | 1.66 | 1.08 | — | 7.30 | 1.69 | 2.21 | 2.76 | 0.90 | 0.90 | 0.76 | 0.63 | 0.53 | 0.36 | 0.33 | 0.30 | 0.23 | 0.21 | 0.18 |
| — | — | -96.6% | -1.8% | -51.2% | — | +711.2% | +87.8% | +191.0% | +335.1% | +69.2% | +150.7% | +133.0% | +108.3% | +127.4% | +70.2% | +78.8% | +85.4% | +54.8% | +51.0% | +38.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | 6.99 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.97 | 10.42 | 10.21 | 4.97 | 4.24 | 2.61 | 3.24 | 4.26 | 4.24 | 5.15 | 6.10 | 6.45 | 7.66 | 8.70 | 8.20 | 8.00 | 7.14 | 6.34 | 6.97 | 9.34 | 7.05 |
| — | +298.6% | +214.9% | +16.9% | +0.1% | -49.2% | -46.9% | -34.0% | -44.6% | -40.8% | -25.6% | -19.4% | +7.3% | +37.2% | +17.7% | -14.3% | +1.3% | -21.4% | -21.6% | -5.0% | -14.6% | |
| Quick Ratio | 4.97 | 10.42 | 10.21 | 4.97 | 4.24 | 2.61 | 3.24 | 4.26 | 4.24 | 4.90 | 5.79 | 6.14 | 7.37 | 8.29 | 7.86 | 7.72 | 6.91 | 6.18 | 6.82 | 9.15 | 6.94 |
| — | +298.6% | +214.9% | +16.9% | +0.1% | -46.6% | -44.0% | -30.6% | -42.5% | -40.9% | -26.3% | -20.5% | +6.6% | +34.2% | +15.3% | -15.6% | -0.4% | -22.3% | -22.1% | -5.6% | -14.9% | |
| Interest Coverage | -5.27 | -5.86 | -4.65 | -2.69 | -4.88 | -6.30 | -8.32 | 1.69 | -5.15 | -7.16 | -5.66 | -5.13 | -6.77 | -7.32 | -20.40 | -6.85 | -7.51 | -20.99 | -10.99 | -16.92 | -9.12 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NKTR stock.
Nektar Therapeutics's current P/E is -7.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Nektar Therapeutics's current operating margin is -236.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nektar Therapeutics's business trajectory between earnings reports.